SHRESTH Initiative Launched to Enhance Drug Quality
Why in the News ?
Union Health Secretary Punya Salila Srivastava launched the State Health Regulatory Excellence Index (SHRESTH) in New Delhi, a CDSCO-led initiative aimed at improving state drug regulatory authorities, ensuring medicine safety, quality, and efficacy through a data-driven benchmarking framework.
Launch and Objectives of SHRESTH Initiative:
- Launched by: Union Health Secretary Punya Salila Srivastava in New Delhi.
- Objective: Strengthen drug safety and quality in India by improving the performance of state drug regulatory authorities.
- Significance: First-of-its-kind national benchmarking system for state regulators.
- Approach:
- Transparent and data-driven framework.
- Recognition of best practices among states and UTs.
- Focus on continuous improvement in drug manufacturing and distribution oversight.
- Minister’s Statement:
- Medicine safety, quality, and efficacy are foundational to public health.
- Called for Centre–State collaboration to uphold high regulatory standards.
Impact and Future Roadmap:
- Expected Outcomes:
- Uniform enforcement of drug quality standards across states.
- Increased accountability and transparency in regulatory performance.
- Improved public trust in medicines manufactured and distributed in India.
- Best Practices Sharing: States with exemplary performance will act as models for others.
- Technological Integration: Future adoption of digital monitoring tools for real-time compliance checks.
- Long-Term Vision:
- Position India as a global leader in safe pharmaceutical production.
- Ensure zero tolerance towards substandard or counterfeit medicines.
About SHRESTH and CDSCO:● SHRESTH: State Health Regulatory Excellence Index. ● Proposed by: Central Drugs Standard Control Organisation (CDSCO) under the Ministry of Health & Family Welfare. ● Purpose: ○ Evaluate and rank state drug regulatory systems. ○ Identify gaps and provide support for capacity building. ● CDSCO’s Role: ○ Acts as the national drug regulatory authority of India. ○ Oversees drug approval, clinical trials, quality control, and licensing. ● Relevance to Governance: ○ Aligns with National Health Policy goals. ○ Enhances India’s pharmaceutical credibility globally. |
